Ramucirumab

Therapeutic Ramucirumab antibody from the original Cyramza® commercial drug

Showing all 6 results

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Isotypes
Expiry Date
Filters Sort results
Product
Antigen
Molecular Class
Drug Brand
Product Concentration
Volume per Vial
Quantity per vial
Storage Temperature
Expiry Date
Price
VEGFR2
Monoclonal Antibody
Cyramza®
10 mg/mL
200 µL
2 mg
-80°C
03/2018
234,00 
view product
Max: 10
Min: 1
Step: 1
VEGFR2
Monoclonal Antibody
Cyramza®
10 mg/mL
200 µL
2 mg
-80°C
06/2018
234,00 
view product
Max: 10
Min: 1
Step: 1
VEGFR2
Monoclonal Antibody
Cyramza®
10 mg/mL
200 µL
2 mg
-80°C
08/2018
234,00 
view product
Max: 10
Min: 1
Step: 1
VEGFR2
Monoclonal Antibody
Cyramza®
10 mg/mL
200 µL
2 mg
-80°C
01/2019
234,00 
view product
Max: 10
Min: 1
Step: 1
VEGFR2
Monoclonal Antibody
Cyramza®
10 mg/mL
200 µL
2 mg
-80°C
12/2019
234,00 
view product
Max: 10
Min: 1
Step: 1
VEGFR2
Monoclonal Antibody
Cyramza®
10 mg/mL
200 µL
2 mg
-80°C
06/2020
234,00 
view product
Max: 10
Min: 1
Step: 1

Not looking for Ramucirumab?

Search our therapeutic molecules product database

Cyramza® / Ramucirumab Reference Product

Drug nameCyramza®
INNRamucirumab
API typeRamucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology.
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
L01XC21
Target of antibody
VEGFR2; Synonyms: CD309, FLK1, VEGFR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced
angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF
Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits
ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components,
including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and
migration of human endothelial cells.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers
EU/1/14/957/001 - 003
Marketing authorisation holder
Eli Lilly Nederland B.V.
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands
Name of the manufacturer of the biological active substance
ImClone Systems LLC
33 ImClone Drive,
Branchburg
New Jersey
NJ 08876
UNITED STATES
Eli Lilly S.A.
Dunderrow
Kinsale
County Cork
Ireland
Name and address of the manufacturer(s) responsible for batch releaseLilly, S.A.
Avda de la Industria, 30
Alcobendas
28108 Madrid
Spain
Max shelf life
36 months
Storage conditions
2°C – 8°C
List of excipients
Histidine
Histidine monohydrochloride
Sodium chloride
Glycine (E640)
Polysorbate 80 (E433)
Water for injections
Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.